
mRNA cancer vaccine shows sustained improvement in survival rates
Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. The combination therapy was also shown to reduce the risk of distant metastasis or… Read More















